Manufacturing & Packaging

Agreement establishes company’s first mRNA manufacturing facility in Africa

The deal features a long-term supply and production agreement between the parties

Expansion features 11 new cGMP labs at Durham, NC location

A chat with Cardinal Health’s Joel Wayment, who dives into what can be done to help ensure that patients receive their necessary medications, no matter the conditions

The parties are partnering up to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies

Turnkey centers will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa

CDMO obtains both Vibalogics and Arranta Bio to increase presence in the sector

Will establish presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden

Plans are underway to build Scottish fill-finish center, renovate API facility in England

The solution is a combination of cold chain logistics, serialization compliance and distribution

With the deal, the China-based CDMO grows its US presence

Anticipated yearly production is 2 million units

Newly acquired Performance Cell Manufacturing will now be known as Cellipont Bioservices

CDMO's new South Korean facility to offer a range of production services

Acquisition of AcKnowledge RS also expands company's IVD expertise

Will welcome seven temperature-controlled processing suites to accommodate various biologic drug needs

Partnership enhances CBM’s manufacturing capabilities in C&GT space

Agreement allows CRO to grow its manufacturing services, including in the chemistry space

Marks the first step in two-phase facility expansion project

Center’s 89,000 square-foot expansion expected to double its capacity

Strategic collaboration will feature Mammoth’s CRISPR know-how to design in vivo therapies

Collaboration aims to prioritize best practices in fields of biopreservation and closed-system manufacturing, while improving children’s health

The shot—which could be the first one to be mRNA based—is scheduled to begin clinical trials later this year

Investment features the construction of a high-throughput screening center

BFS technology deal expected to be finalized in Q1